PFIZER INC reported on Saturday that its experimental monthly obesity injection, berobenatide, achieved up to 12.3% weight loss in mid-stage trial patients. The results position the drug as a viable monthly alternative to weekly treatments currently dominating the metabolic market. Success is critical for PFIZER INC after it was forced to discontinue two previous weight-loss candidates due to liver safety concerns.

Clinical Data Aligns with Market Expectations